Current Perspectives of Anticoagulation in Patients With COVID-19
Current Perspectives of Anticoagulation in Patients With COVID-19
复制标题
DOI：
10.1097/fjc.0000000000000861
复制
发表时间：
2020-08-01
影响因子：
3
通讯作者：
Vider, Etty
中科院分区：
文献类型：
--
作者：
Gavioli, Elizabeth M.;Sikorska, Gabriela;Vider, Etty
血栓栓塞和心肌损伤在COVID-19患者中很常见。低分子量肝素似乎与COVID-19患者的良好预后相关，并具有降低凝血和炎症标志物的能力。对于高风险或机械通气患者，应将COVID-19住院患者置于血栓预防治疗，并选择全面治疗性抗凝或组织纤溶酶原激活剂。高危患者出院时也应考虑血栓预防。在没有确认数据的COVID-19患者中，应使用临床判断来评估抗凝治疗的出血和安全性风险。
Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.